Table 3.
Palivizumab recovery from human milk and infant digestates with different extraction methods for removal of sample background neutralization effects.
| Expt. No. | Purification method | Palivizumab recovery, % | ||
|---|---|---|---|---|
| Human milk | Gastric | Intestinal | ||
| 2.2.1 | Centrifugation (11,292 g) and 0.2-μm filtration | 80.57 | 100.46 | – |
| 2.2.2 | Centrifugation (4,000 g), 100-kDa MWCO and 0.2-μm filtration | 83.49 | 59.32 | 92.51 |
| 2.2.3 | Salting out | 10.25 | – | – |
| 2.2.4 | Skimming fat, casein precipitation, 0.2-μm filtration and 100-kDa MWCO | 8.76 | – | – |
| 2.2.5 | Protein A column (Gravity-flow method) | 25.15 | 1.89 | – |
| 2.2.6 | Protein G spin plate (low-pH elution) | 60.13 | 38.20 | 73.32 |
| 2.2.7 | Protein G spin plate (low-pH elution) and 100-kDa MWCO | 2.73 | 2.14 | 2.94 |
| 2.2.8 | Protein G spin plate (low-pH elution) and 100-kDa dialysis |
22.86 | 12.94 | 9.05 |
| 2.2.9 | Protein G spin column (high-salt elution and 30-kDa MWCO) | 64.20 | 77.25 | 71.07 |
–: Not determined.